metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O-9 THE CHANGING EPIDEMIOLOGY OF HEPATOCELLULAR CARCINOMA IN SOUTH AMERICA: A RE...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(Marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(Marzo 2023)
Acceso a texto completo
O-9 THE CHANGING EPIDEMIOLOGY OF HEPATOCELLULAR CARCINOMA IN SOUTH AMERICA: A REPORT FROM THE SOUTH AMERICAN LIVER RESEARCH NETWORK
Visitas
179
Enrique Carrera Estupinan1, Angelo Mattos2, Javier Diaz Ferrer3, Marina Farah4, Domingo Balderramo5, Estefania Liza Vaca3, Marco Arrese Jimenez6, Jhon Prieto Ortiz7, Jose Debes8
1 Department of Gastroenterology and Hepatology, Eugenio Espejo Hospital, Quito, Ecuador
2 Department of Gastroenterology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil
3 Department of Gastroenterology, National Hospital Edgardo Rebagliati Martins, Jesús María, Perú
4 American University of Beirut
5 Private University Hospital of Córdoba. University Institute of Biomedical Sciences of Córdoba. Córdoba, Argentina
6 Department of Gastroenterology, Pontifical Catholic University of Chile. Santiago, Chile
7 Liver and Digestive Disease Center (CEHYD), Bogotá, Colombia
8 Department of Medicine, University of Minnesota. Minnesota, USA
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide and most epidemiological data originates from resource-rich countries. We have previously described the epidemiology of HCC in South America through the South American Liver Research Network (SALRN). Here, we provide an update on the changing epidemiology of HCC in the continent over the last two years.

Materials and Methods

We evaluated HCC cases diagnosed between 2019 to 2021 in six centers from six countries in South America. A retrospective chart review of patient characteristics at the time of HCC diagnosis, including demographic, clinical and laboratory data, was completed. Diagnosis of HCC was made radiologically or histologically for all cases via institutional standards. Each center provided ethical approval for the study.

Results

A total of 339 HCC cases were included [Peru 37% (n = 125), Brazil 16% (n = 57), Chile 15% (n =51), Colombia, 14% (n = 48), Ecuador 9% (n = 29) and Argentina, 9% (n = 29)]. 61% of patients were male and the median age of diagnosis was 67 years (IQR 59-73). The most common risk factor for HCC was nonalcoholic fatty liver disease NAFLD (37%), followed by Hepatitis C infection (17%), alcohol use disorder (11%) and Hepatitis B infection (12%). The proportion of NAFLD-related HCC was much higher than in our previous report (37% compared to 11%). The majority of HCCs occurred in the setting of cirrhosis (80%), and the most common cause of non-cirrhotic HCC was HBV (31%) and NAFLD (28%). HBV-related HCC occurred at a younger age compared to other causes, with a median age of 46 years (IQR 36-64).

Conclusions

We report changes in the epidemiology of HCC in South America over the last 10 years, with a substantial increase in NAFLD-related HCC. HBV-related HCC still occurs at a much younger age when compared to other causes.

El Texto completo está disponible en PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos